CCR
Os receptores de quimiocinas C-C (CCRs) são um grupo de GPCRs que respondem às quimiocinas, moléculas de sinalização que orientam a migração de células imunológicas para locais de inflamação ou infecção. Os CCRs desempenham papéis cruciais nas respostas imunológicas, inflamação e no desenvolvimento de várias doenças, incluindo distúrbios autoimunes e câncer. A modulação da atividade dos CCRs está sendo explorada como uma estratégia terapêutica para condições como artrite reumatoide, esclerose múltipla e infecção pelo HIV. Na CymitQuimica, oferecemos uma gama de moduladores de CCR de alta qualidade para apoiar sua pesquisa em imunologia, inflamação e desenvolvimento terapêutico.
Foram encontrados 136 produtos de "CCR"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Leronlimab
CAS:<p>Leronlimab (PRO 140), a humanized IgG4 monoclonal antibody, targets CCR5 to combat HIV and cancer.</p>Pureza:SDS-PAGE:95.0%;SEC-HPLC:99.6%Cor e Forma:LiquidPeso molecular:146.66 kDaMogamulizumab
CAS:<p>Mogamulizumab is a monoclonal antibody targeting CC chemokine receptor 4 with anticancer effects, used in ATLL and CTCL studies.</p>Pureza:SDS-PAGE:97.3%;SEC-HPLC:99.4%Cor e Forma:LiquidPeso molecular:146.43 kDaINCB-9471
CAS:<p>INCB-9471 is a CCR5 antagonist with anti-HIV activity and inhibits the interaction between HIV-1 gp120.</p>Fórmula:C30H40F3N5O2Pureza:98.80%Cor e Forma:SolidPeso molecular:559.666CCR2-RA-[R]
CAS:<p>CCR2-RA-[R] is a C-C chemokine receptor type 2 (CCR2) allosteric antagonist (IC50: 103 nM).</p>Fórmula:C18H19ClFNO3Pureza:99.7%Cor e Forma:SolidPeso molecular:351.8CCX140
CAS:<p>CCX140 (CCX140-B) (CCX140-B) is an antagonist of CCR2.</p>Fórmula:C20H13ClF3N5O3SPureza:99.66% - 99.95%Cor e Forma:SolidPeso molecular:495.86AZ084
CAS:<p>AZ084 is a potent, selective, allosteric, and oral active CCR8 antagonist (Ki: 0.9 nM). It has the potential to treat asthma.</p>Fórmula:C26H34N4O2Pureza:97.12%Cor e Forma:SolidPeso molecular:434.57ML604086
CAS:<p>ML604086 suppresses CCL1 mediated chemotaxis and enhances intracellular Ca2 concentrations.</p>Fórmula:C27H32N4O4SPureza:99.91%Cor e Forma:SolidPeso molecular:508.63RS102895 hydrochloride
CAS:<p>RS102895 hydrochloride is a potent antagonist of CCR2(IC50 of 360 nM).</p>Fórmula:C21H22ClF3N2O2Pureza:98.95%Cor e Forma:SolidPeso molecular:426.86MK-0812 Succinate
CAS:<p>MK-0812 Succinate is an effective and selective CCR2 antagonist.</p>Fórmula:C28H40F3N3O7Pureza:98.62% - 99.93%Cor e Forma:SolidPeso molecular:587.63J-113863
CAS:<p>J-113863 is also a potent antagonist of the human CCR3 (IC50 of 0.58 nM) , but a weak antagonist of the mouse CCR3 (IC50 of 460 nM).</p>Fórmula:C30H37Cl2IN2O2Pureza:95.11%Cor e Forma:SolidPeso molecular:655.44CCR4 antagonist 3
CAS:<p>Orally active CCR4 antagonist with piperidinyl-azetidine; IC50: 22 nM (calcium flux), 50 nM (CTX); antitumor effects.</p>Fórmula:C24H27Cl2N7OCor e Forma:SolidPeso molecular:500.43Plozalizumab
CAS:<p>Plozalizumab (MLN-1202) is a humanized selective and potent anti-CCR2 antibody.Plozalizumab has antitumor activity.Plozalizumab is used in the study of</p>Pureza:96.4%Cor e Forma:LiquidPeso molecular:146.02 kDaCCR8 antagonist 1
CAS:<p>CCR8 antagonist 1 is an antagonist of C-C Motif Chemokine Receptor 8 (CCR8) with a Ki value of 1.6 nM.</p>Fórmula:C26H29N3O5SPureza:99.51%Cor e Forma:SolidPeso molecular:495.59Denikitug
<p>Denikitug is a chimeric antibody of the IgG1κ type that targets CCR8, with its corresponding isotype control being HumanIgG1kappa, Isotype Control.</p>Cor e Forma:Odour LiquidLanerkitug
<p>Lanerkitug is a humanized IgG1λ2 antibody that targets CCR8, with HumanIgG1lambda2, Isotype Control serving as its corresponding isotype control.</p>Cor e Forma:Odour LiquidCCR4 antagonist 3 hydrochloride
CAS:<p>Orally active CCR4 antagonist 3 hydrochloride with potent selectivity, IC50s: 22/50 nM; has antitumor properties.</p>Fórmula:C24H27Cl2N7O·xHClCor e Forma:SolidSQA1
CAS:<p>SQA1 is a derivative of a phthalamide (SQA) and acts as a CCR6 antagonist with a Kd of 250 nM, as well as a CXCR2 inhibitor. It occupies an intracellular pocket that overlaps with the G protein binding site, stabilizing the pocket's closed conformation.</p>Fórmula:C22H26N4O5Cor e Forma:SolidPeso molecular:426.47Zn-DPA-maytansinoid conjugate 1
<p>Zn-DPA-maytansinoid 1 targets checkpoints, shrinks tumors, and heats TME.</p>Fórmula:C115H145ClN18O31S2Zn2Cor e Forma:SolidPeso molecular:2505.83Maceneolignan H
CAS:<p>Maceneolignan H, a neolignane from Myristica fragrans, selectively blocks CCR3 (EC50=1.4μM) with allergy research potential.</p>Fórmula:C24H30O7Cor e Forma:SolidPeso molecular:430.49CKLF1-C27 TFA
<p>CKLF1-C27 peptide activates ERK1/2 via CCR4, competes with CKLF1, promotes HUVEC growth, and has psoriasis research potential.</p>Fórmula:C153H244F3N39O39Cor e Forma:SolidPeso molecular:3310.8CCR2 antagonist 1
CAS:<p>CCR2 antagonist 1 is a high-affinity and long-residence-time antagonist of CCR2 (Ki: 2.4 nM).</p>Fórmula:C28H32BrF3N2OCor e Forma:SolidPeso molecular:549.47Denrakibart
<p>Denrakibart is a humanized IgG2κ antibody targeting CCL17, with HumanIgG2kappa, Isotype Control serving as the corresponding isotype control.</p>Cor e Forma:Odour LiquidAzirkitug
<p>Azirkitug is a humanized IgG1κ antibody targeting CCR8, with HumanIgG1kappa, Isotype Control serving as its corresponding isotype control.</p>Cor e Forma:Odour LiquidINCB 3284 dimesylate
CAS:<p>INCB 3284 dimesylate: oral CCR2 antagonist, blocks MCP-1/hCCR2 binding (IC50: 3.7 nM), potential in acute liver failure research.</p>Fórmula:C28H39F3N4O10S2Pureza:98%Cor e Forma:SolidPeso molecular:712.76Nebokitug
<p>Nebokitug is a humanized IgG1κ antibody targeting CCL24, with HumanIgG1kappa, Isotype Control serving as its corresponding isotype control.</p>Cor e Forma:Odour LiquidCafelkibart
<p>Cafelkibart is a chimeric IgG1κ monoclonal antibody targeting CCR8, with HumanIgG1kappa, Isotype Control serving as its corresponding isotype control.</p>Cor e Forma:Odour LiquidCCR6 inhibitor 1
CAS:<p>CCR6 inhibitor 1 selectively blocks CCR6 (0.45 nM in monkeys, 6 nM in humans), aiding in vitro/vivo disease studies.</p>Fórmula:C24H23F3N4O3SPureza:99.89%Cor e Forma:SolidPeso molecular:504.522-Methoxyhydroquinone
CAS:<p>2-Methoxyhydroquinone inhibits MAO-A and MAO-B and reduces TNF-α-induced CCL2 production, a precursor for synthesising the Hsp90 inhibitor Geldanamycin.</p>Fórmula:C7H8O3Pureza:98.25%Cor e Forma:SolidPeso molecular:140.14CAP-100
<p>CAP-100 is a monoclonal antibody targeting CCR7. It neutralizes the ligand binding site and signaling of CCR7. This compound effectively inhibits migration, extravasation, homing, and survival in chronic lymphocytic leukemia (CLL) samples induced by CCR7. CAP-100 can mediate potent tumor cell killing through host immune mechanisms and exhibits favorable toxicity profiles in related hematopoietic cell subsets. It is involved in research on antitumor activity and diseases like chronic lymphocytic leukemia (CLL).</p>Cor e Forma:Odour LiquidChemokine Inhibitor Library
<p>A unique collection of xnum chemokines or chemokine receptors targeted compounds for high throughput and high content screening;</p>Cor e Forma:Odour SolidWAY-639418
CAS:<p>WAY-639418 has potential anti-inflammatory and anti-HIV activity and can be used to study CCR5-mediated inflammatory and immunomodulatory diseases.</p>Fórmula:C17H16ClN5Pureza:99.62%Cor e Forma:SolidPeso molecular:325.8CCR8 agonist 1
<p>CCR8 agonist1 (Compound 2) is an activator of CCR8 and is applicable in studies related to autoimmune diseases.</p>Fórmula:C22H29NO3Cor e Forma:SolidPeso molecular:355.47BMS-753426
CAS:<p>BMS-753426 is a potent and orally bioavailable antagonist of CCR2 .</p>Fórmula:C25H33F3N6O2Cor e Forma:SolidPeso molecular:506.574PF-232798
CAS:<p>PF-232798 is a second generation oral CCR5 antagonist with potent broad-spectrum anti-HIV-1 activity.</p>Fórmula:C29H40FN5O2Cor e Forma:SolidPeso molecular:509.66CCR6 antagonist 1
CAS:<p>CCR6 antagonist 1 blocks CCL20/CCR6, aiding autoimmune and IBD research.</p>Fórmula:C17H12F3NO2Pureza:99.83%Cor e Forma:SoildPeso molecular:319.28NI-0701
<p>NI-0701 is a humanized antibody targeting CCL5/RANTES.</p>Pureza:95.4% (SDS-PAGE); 99.4% (SEC-HPLC) - 95.4% (SDS-PAGE); 99.4% (SEC-HPLC)Cor e Forma:LiquidPeso molecular:145.5kDaINCB3344 R-isomer
<p>INCB3344 is a potent CCR2 antagonist. INCB3344 R-isomer is the R-isomer of INCB3344.</p>Fórmula:C29H34F3N3O6Pureza:98%Cor e Forma:SolidPeso molecular:577.59CHS-114
<p>CHS-114 (SRF-114) is a fully human IgG1 antibody targeting the (CCR8) receptor. It shows potential for research in head and neck squamous cell carcinoma (HNSCC). The isotype control for CHS-114 can be referred to as HumanIgG1kappa, Isotype Control.</p>Cor e Forma:Odour LiquidCCR6 antagonist 2
<p>CCR6 antagonist2 (Compound 20c) acts as a CCR6 antagonist with a Ki of 1.1 nM. It inhibits CCL20-induced calcium influx with an IC50 of 4.9 nM and suppresses the chemotactic migration of CCR6+ T cells with an IC50 of 190 nM.</p>Fórmula:C19H24N4O4Cor e Forma:SolidPeso molecular:372.42GSK-3050002
<p>GSK-3050002 (HGS-1035) is a humanized IgG1 antibody that targets and binds to CCL20. It holds potential for inflammation research. For isotype control, refer to Human IgG1 kappa, Isotype Control.</p>Cor e Forma:Odour LiquidMet-RANTES,human,acetate
<p>Met-RANTES (human) acetate is the acetate salt form of Met-RANTES (human). It acts as an antagonist for CCR1 and CCR5 receptors. This compound inhibits the human chemokines MIP-1α and MIP-1β, with respective IC50 values of 5 and 2 nM. Additionally, Met-RANTES (human) acetate reduces bone destruction and alleviates adjuvant-induced arthritis (AIA) in rats.</p>Cor e Forma:Odour SolidMLN-3897 TFA
<p>MLN-3897 TFA is a potent CCR1 antagonist that inhibits the binding of 125I-MIP-1α to THP-1 cell membranes.</p>Fórmula:C32H32ClF3N2O6Pureza:98.62%Cor e Forma:SolidPeso molecular:633.05CH-0076989
CAS:<p>CH-0076989 is a chemokine receptor CCR3 agonist.</p>Fórmula:C24H22Br2N2O2Cor e Forma:SolidPeso molecular:530.25Bertilimumab
CAS:<p>Bertilimumab (CAT 213; iCo-008), a human monoclonal antibody that targets eotaxin-1 (CCL11), shows promise in the research of allergic disorders [1].</p>Cor e Forma:LiquidCCR2 antagonist 4 hydrochloride
CAS:<p>CCR2 antagonist 4 hydrochloride is a specific CCR2 antagonist (IC50s: 180 nM for CCR2b). It potently inhibits MCP-1-induced chemotaxis (IC50: 24 nM).</p>Fórmula:C21H22Cl2F3N3O2Cor e Forma:SolidPeso molecular:476.32TAK-779
CAS:<p>TAK-779 (Takeda 779) is an antagonist of chemokine receptor 5 (CCR5), CCR2b, and CXC chemokine receptor 3 (CXCR3).</p>Fórmula:C33H39ClN2O2Pureza:99.21%Cor e Forma:SolidPeso molecular:531.13ZK 756326
CAS:<p>ZK 756326: Selective CCR8 agonist, IC50 1.8 μM (human), 2.6 μM (mouse), no CCR4/5, CXCR3/4 action, 28-fold selectivity vs 26 GPCRs, anti-HIV fusion.</p>Fórmula:C21H28N2O3Pureza:99.43%Cor e Forma:SolidPeso molecular:356.46PF-4136309
CAS:<p>PF-4136309 (INCB8761) is a specific, effective, and orally bioavailable CCR2 antagonist.</p>Fórmula:C29H31F3N6O3Pureza:98.85% - 99.47%Cor e Forma:SolidPeso molecular:568.59RS102895
CAS:<p>RS102895 is a potent CCR2 antagonist (IC50: 360 nM) and shows no effect on CCR1.</p>Fórmula:C21H21F3N2O2Pureza:97.64% - 99.80%Cor e Forma:SolidPeso molecular:390.4AZD-4818
CAS:<p>AZD-4818 (CCR1 antagonist) is a chemokine CCR1 antagonist for the treatment of chronic obstructive pulmonary disease.</p>Fórmula:C27H32Cl2N2O7Pureza:99.01%Cor e Forma:SolidPeso molecular:567.46Vercirnon
CAS:<p>Vercirnon (Traficet-EN) is a selective and potent antagonist of CCR9 (IC50: 10 nM). It is also used in the research of inflammatory bowel diseases.</p>Fórmula:C22H21ClN2O4SPureza:99.23%Cor e Forma:SolidPeso molecular:444.93Maraviroc
CAS:<p>Maraviroc: a CCR5 antagonist blocking HIV-1 entry; IC50s—MIP-1α: 3.3nM, MIP-1β: 7.2nM, RANTES: 5.2nM.</p>Fórmula:C29H41F2N5OPureza:97.13% - 99.59%Cor e Forma:Brown SolidPeso molecular:513.67C-021
CAS:<p>C 021 dihydrochloride is a potent CCR4 antagonist.</p>Fórmula:C27H41N5O2Pureza:99.74% - 99.90%Cor e Forma:SolidPeso molecular:467.65R243
CAS:<p>R243 is CCR8 signaling and chemotaxis inhibitor.</p>Fórmula:C21H27NO4Pureza:99.03%Cor e Forma:SolidPeso molecular:357.44RE-640
CAS:<p>NSC-5844 (RE-640) (RE640) is a bisquinoline compound with C-C chemokine receptor type 1 (CCR1)-agonistic activities.</p>Fórmula:C20H16Cl2N4Pureza:99.60% - 99.87%Cor e Forma:SolidPeso molecular:383.27Vicriviroc maleate
CAS:<p>Vicriviroc maleate (SCH-417690 (maleate))(Sch-417690) is a piperazine-based CCR5 receptor antagonist with activity against human immunodeficiency virus.</p>Fórmula:C32H42F3N5O6Pureza:98.16% - 98.37%Cor e Forma:SolidPeso molecular:649.7BX471
CAS:<p>BX471 (BX 471) is a potent, selective non-peptide CCR1 antagonist.</p>Fórmula:C21H24ClFN4O3Pureza:98% - 99.94%Cor e Forma:SolidPeso molecular:434.89SB297006
CAS:<p>SB297006 is an antagonist of C-C chemokine receptor 3, which normally is activated by eotaxin, eotaxin-3, MCP-3, MCP-4, RANTES, and MIP-1δ.</p>Fórmula:C18H18N2O5Pureza:99.59%Cor e Forma:SolidPeso molecular:342.35Bindarit
CAS:<p>Bindarit is a selective inhibitor of monocyte chemoattractant proteins MCP-1/CCL2, MCP-3/CCL7 and MCP-2/CCL8.Cost-effective and quality-assured.</p>Fórmula:C19H20N2O3Pureza:98.35% - 98.55%Cor e Forma:SolidPeso molecular:324.377,4'-Dihydroxyflavone
CAS:<p>7,4'-Dihydroxyflavone (4',7-Dihydroxyflavone) can induce transcription of nodulation (nod) genes in Rhizobium meliloti.</p>Fórmula:C15H10O4Pureza:99.39% - 99.6%Cor e Forma:SolidPeso molecular:254.24RS 504393
CAS:<p>RS 504393 is a highly selective CCR2 chemokine receptor antagonist (IC50s: 89 nM and > 100 μM for human recombinant CCR2 and CCR1).</p>Fórmula:C25H27N3O3Pureza:98.64% - 99.62%Cor e Forma:SolidPeso molecular:417.5BMS-813160
CAS:<p>BMS-813160 is the first dual CCR2/CCR5 antagonist to enter Clinical development for cardiovascular.</p>Fórmula:C25H40N8O2Pureza:99.66% - 99.79%Cor e Forma:SolidPeso molecular:484.64DAPTA
CAS:<p>DAPTA (Adaptavir) is an inhibitor of CCR5, shows potent anti-HIV activities.</p>Fórmula:C35H56N10O15Pureza:>99.99%Cor e Forma:SolidPeso molecular:856.88Vercirnon sodium
CAS:<p>Vercirnon (GSK1605786A) sodium: oral CCR9 antagonist, inhibits Ca2+ mobilization/chemotaxis, IC50 = 2.6-5.4 nM, selective for CCR9 vs. CCR1-12/CX3CR1-7.</p>Fórmula:C22H21ClN2NaO4SCor e Forma:SolidPeso molecular:467.92AZD2098
CAS:<p>AZD2098 is a potent CC-chemokine receptor 4 (CCR4) inhibitor used for asthma research.</p>Fórmula:C11H9Cl2N3O3SPureza:99.80% - >99.99%Cor e Forma:SolidPeso molecular:334.18Cenicriviroc
CAS:<p>Cenicriviroc (TAK-652), oral CCR2/CCR5 blocker, inhibits HIV-1/HIV-2, with strong anti-infective/anti-inflammatory effects.</p>Fórmula:C41H52N4O4SPureza:97.87%Cor e Forma:SolidPeso molecular:696.94INCB 3284
CAS:<p>INCB 3284, a potent human CCR2 antagonist with an IC50 of 3.7 nM, is researchable for acute liver failure and inhibits MCP-1/hCCR2 binding.</p>Fórmula:C26H31F3N4O4Pureza:97.81% - 99.42%Cor e Forma:SolidPeso molecular:520.54Carlumab
CAS:<p>Carlumab is a high-affinity human monoclonal antibody that targets CCL2, suppressing the recruitment of monocytes/macrophages in the tumour microenvironment.</p>Pureza:95%Cor e Forma:LiquidTivumecirnon
CAS:<p>Tivumecirnon (FLX475) is a selective and oral CCR4 antagonist inhibits the infiltration and migration of Treg into the tumour microenvironment, antitumour</p>Fórmula:C24H27Cl2F3N6OPureza:99.88%Cor e Forma:SolidPeso molecular:543.41BI-6901
CAS:<p>BI-6901 is a CCR10 antagonist. In a mouse model of DNFB exposure hypersensitivity, BI 6901 displays its anti-inflammatory response in a dose-dependent manner.</p>Fórmula:C23H27N5O3SPureza:99.83%Cor e Forma:SolidPeso molecular:453.56CCR4 antagonist 3-1
CAS:<p>CCR4 antagonist 3-1 is a weak inhibitor of [125I]TARC binding and CEM cell migration, with IC50 values of 1.7 μM and 6.4 μM, respectively.</p>Fórmula:C14H12N2SPureza:99.53%Cor e Forma:SolidPeso molecular:240.32CCR1 antagonist 9
CAS:<p>CCR1 antagonist 9 (compound 19e) is a selective CCR1 antagonist based on aziridine. CCR1 inhibition in calcium flux assays.</p>Fórmula:C20H16FN5O3SPureza:99.13%Cor e Forma:SolidPeso molecular:425.44CCR8 antagonist 2
CAS:<p>CCR8 antagonist 2 blocks CCR8 activity, mainly on Treg and Th2 cells, for treating related diseases. See WO2022000443A1, compound 220.</p>Fórmula:C23H30ClN3O3SCor e Forma:SolidPeso molecular:464.02YM022
CAS:<p>YM022 is a highly effective and selective gastrin/cholecystokinin (CCK)-B receptor antagonist.</p>Fórmula:C32H28N4O3Pureza:98%Cor e Forma:SolidPeso molecular:516.59CCR2 antagonist 3
CAS:<p>CCR2 antagonist 3 (AZD-2927) is an antagonist of CCR2.</p>Fórmula:C17H25FN2O2Pureza:99.87%Cor e Forma:SolidPeso molecular:308.39GW 766994
CAS:<p>GW 766994 is a specific and oral chemokine receptor-3 (CCR3) antagonist. It has the potential for asthma and eosinophilic bronchitis treatment.</p>Fórmula:C21H24Cl2N4O3Pureza:98.77%Cor e Forma:SolidPeso molecular:451.35CCR1 antagonist 7
CAS:<p>CCR1 antagonist 7 (compound 16r) is an antagonist of chemokine receptor 1 (CCR1) with an IC 50 of 4 nM [1].</p>Fórmula:C21H24ClN5O3SPureza:98%Cor e Forma:SolidPeso molecular:461.96RPT193
CAS:<p>RPT193 is an oral CCR4 inhibitor reducing Th2 cell migration in atopic dermatitis, asthma, and allergies.</p>Fórmula:C27H34Cl3N5O2Cor e Forma:SolidPeso molecular:566.95ALK4290
CAS:<p>ALK4290 (AKST4290), a potent oral CCR3 inhibitor with a Ki of 3.2 nM, may treat macular degeneration and Parkinsonism.</p>Fórmula:C27H34ClN5O3Cor e Forma:SolidPeso molecular:512.04CCX354
CAS:<p>CCX354 (CCR1 antagonist 1) is a potent small molecule CCR1 antagonist with anti-inflammatory activity for the treatment of rheumatoid arthritis.</p>Fórmula:C22H22ClN7O2Pureza:99.82% - 99.82%Cor e Forma:SolidPeso molecular:451.91PNU-177864 hydrochloride
CAS:<p>PNU-177864 hydrochloride is a potent, selective and orally active antagonist of dopamine D3 receptor.</p>Fórmula:C18H22ClF3N2O3SPureza:99.95%Cor e Forma:SolidPeso molecular:438.89PNU-177864
CAS:<p>PNU-177864 is a selective dopamine D3 receptor antagonist.</p>Fórmula:C18H21F3N2O3SPureza:99.92%Cor e Forma:SolidPeso molecular:402.43BMS-457
CAS:<p>BMS-457 is a potent, CCR1-selective antagonist.</p>Fórmula:C24H35ClN2O4Pureza:98%Cor e Forma:SolidPeso molecular:451AZD-1678
CAS:<p>AZD-1678 is a potent CCR4 receptor antagonist.</p>Fórmula:C11H8Cl2FN3O3SCor e Forma:SolidPeso molecular:352.17MLN3126
CAS:<p>MLN3126: Oral CCR9 blocker, hinders CCL25-triggered chemotaxis/thymocyte calcium influx, IC50 of 6.3 nM.</p>Fórmula:C21H19ClN2O5SCor e Forma:SolidPeso molecular:446.9JNJ-27141491
CAS:<p>JNJ-27141491 is a potent, noncompetitive antagonist of human CCR2.</p>Fórmula:C17H15F2N3O3SPureza:98%Cor e Forma:SolidPeso molecular:379.38TAK-220
CAS:<p>TAK-220: Oral CCR5 antagonist. IC50: 3.5 nM (RANTES), 1.4 nM (MIP-1α).</p>Fórmula:C31H41ClN4O3Pureza:98%Cor e Forma:SolidPeso molecular:553.14C-021 dihydrochloride
CAS:<p>C-021 dihydrochloride is a potent CCR4 antagonist. It potently inhibits functional chemotaxis in human and mouse with IC50s of 140 nM and 39 nM.</p>Fórmula:C27H43Cl2N5O2Pureza:98.67%Cor e Forma:SolidPeso molecular:540.57CCR1 antagonist 6
CAS:<p>CCR1 antagonist 6 is a CCR1 antagonist (IC50: 3 nM).</p>Fórmula:C21H23ClN4O3SPureza:99.02% - 99.15%Cor e Forma:SolidPeso molecular:446.95Ancriviroc
CAS:<p>Ancriviroc (SCH-351125) is an orally bioavailable small molecule chemokine receptor CCR5 antagonist.Cost-effective and quality-assured.</p>Fórmula:C28H37BrN4O3Pureza:99.76% - 99.82%Cor e Forma:SolidPeso molecular:557.52BMS CCR2 22
CAS:<p>BMS CCR2 22 is a potent and selective antagonist of CCR2 with calcium flux IC50 of 18 nM, chemotaxis IC50 of 1 nM, and binding IC50 of 5.1 nM.</p>Fórmula:C28H34F3N5O4SPureza:99.65%Cor e Forma:SolidPeso molecular:593.66CCR2 antagonist 5
CAS:<p>JNJ-41443532: oral hCCR2 antagonist, IC50=37 nM, anti-chemotaxis, treats inflammation & diabetes.</p>Fórmula:C22H25F3N4O3SPureza:99.09%Cor e Forma:SolidPeso molecular:482.52BMS-817399
CAS:<p>BMS-817399: oral CCR1 antagonist with binding and chemotaxis inhibition IC50s, potential for rheumatoid arthritis research.</p>Fórmula:C23H36ClN3O4Pureza:99.7%Cor e Forma:SolidPeso molecular:454SB 328437
CAS:<p>SB 328437 ((S)-methyl 2-(1-naphthamido)-3-(4-nitrophenyl)propanoate) is an effective and selective antagonist of CCR3 (IC50 = 4.5 nM).</p>Fórmula:C21H18N2O5Pureza:99.54%Cor e Forma:SolidPeso molecular:378.38Cosalane
CAS:<p>Cosalane (NSC 658586) is an HIV replication inhibitor and an inhibitor of chemokine receptor 7 (CCR7) signalling in humans and mice.</p>Fórmula:C45H60Cl2O6Pureza:99.53% - 99.78%Cor e Forma:SolidPeso molecular:767.86GSK2239633A
CAS:<p>GSK2239633A is an allosteric antagonist of CC-chemokine receptor 4 (CCR4) with a pIC50 of 7.96 for the binding of [125I]-TARC to human CCR4.</p>Fórmula:C24H25ClN4O5S2Pureza:99.82%Cor e Forma:SolidPeso molecular:549.06VCH-286
CAS:<p>VCH-286 is a C-C chemokine receptor type 5 (CCR5) receptor antagonist.</p>Fórmula:C34H50F2N4O3Pureza:98%Cor e Forma:SolidPeso molecular:600.78PF-04634817 succinate
CAS:<p>PF-0463481 succinate is a potent and orally active dual antagonist of CCR2/CCR5 with comparable human and rodent CCR2 potency with IC50 of 20.8 nM.</p>Fórmula:C29H42F3N5O7Pureza:98%Cor e Forma:SolidPeso molecular:629.67CCR2 antagonist 4
CAS:<p>CCR2 antagonist 4 (Teijin compound 1) is a potent and specific antagonist of CCR2(IC50s of 180 nM), and potently inhibits MCP-1-induced chemotaxis(IC50 of 24 nM</p>Fórmula:C21H21ClF3N3O2Pureza:99.86%Cor e Forma:SolidPeso molecular:439.86CCR4 antagonist 4
CAS:<p>CCR4 Antagonist 4 (Compound 22) is a potent and selective antagonist of the CC chemokine receptor-4 (CCR4), displaying an IC50 value of 0.02 μM. It also inhibits MDC-mediated chemotaxis and Ca2+ mobilization, with IC50 values of 0.007 μM and 0.003 μM, respectively. This compound is utilized in research on allergic inflammation [1].</p>Fórmula:C24H27Cl2N7OCor e Forma:SolidPeso molecular:500.42IPG7236
CAS:<p>IPG7236, a selective CCR8 antagonist, demonstrates notable tumor suppression in a mouse xenograft model of human breast cancer and is applicable in cancer</p>Fórmula:C23H31N3O3SPureza:98%Cor e Forma:SolidPeso molecular:429.58(1S)-CCR2 antagonist 1
CAS:<p>(1S)-CCR2 antagonist 1, a left-handed chiral form of CCR2 antagonist 1, exhibits high affinity and a long residence time as a CCR2 antagonist, with an inhibition constant (K i) of 2.4 nM [1].</p>Fórmula:C28H32BrF3N2OCor e Forma:SolidPeso molecular:549.47MLN-3897
CAS:<p>MLN-3897 is an oral CCR1 antagonist, Ki 2.3 nM, blocks 125I-MIP-1α binding, and inhibits Akt signaling in MM cells.</p>Fórmula:C30H31ClN2O4Pureza:98.62%Cor e Forma:SolidPeso molecular:519.03AZD2423
CAS:<p>AZD2423 is a potent, selective, orally bioavailable, and non-competitive CCR2 chemokine receptor negative allosteric modulator and it has an IC50 of 1.2 nM for</p>Fórmula:C20H29ClFN5O2Pureza:98%Cor e Forma:SolidPeso molecular:425.93SB-649701
CAS:<p>SB-649701 is a potent antagonist of the human CCR8 receptor, exhibiting a pIC50 value of 7.7, and is utilized in asthma research [1].</p>Fórmula:C27H28N4O3Pureza:98%Cor e Forma:SolidPeso molecular:456.54cis-J-113863
CAS:<p>Cis-J-113863 is a competitive antagonist for the chemokine receptor 1 (CCR1), demonstrating inhibitory concentration 50 (IC50) values of 0.9 nM for human CCR1 receptors and 5.8 nM for mouse CCR1 receptors, respectively [1].</p>Fórmula:C30H37Cl2IN2O2Cor e Forma:SolidPeso molecular:655.44PF-04634817
CAS:<p>PF-0463481: safe, well-tolerated, dual CCR2/CCR5 antagonist for diabetic nephropathy; similar human/rodent CCR2 potency, less rodent CCR5 effect.</p>Fórmula:C25H36F3N5O3Pureza:98%Cor e Forma:SolidPeso molecular:511.58(Rac)-PF-4136309(1341224-83-6 Free base)
CAS:<p>PF-4136309 (INCB8761, PF-04136309) is a highly effective and selective oral CCR2 antagonist with good bioavailability, with an IC50 value of 5.2 nM for human</p>Fórmula:C29H31F3N6O3Cor e Forma:SolidPeso molecular:568.59CMPD167
CAS:<p>CMPD167 (MRK-1) is a potent, orally active inhibitor of CCR5 with significant in vitro antiviral efficacy [1].</p>Fórmula:C35H47FN4O2Pureza:98%Cor e Forma:SolidPeso molecular:574.77RP-23618
CAS:<p>RP-23618 is a non-peptidic antagonist of RANTES.</p>Fórmula:C30H35N5O3S2Pureza:98%Cor e Forma:SolidPeso molecular:577.76trans-J-113863
CAS:<p>Trans-J-113863 serves as a potent antagonist of chemokine receptors CCR1 and CCR3, effectively inhibiting MIP-1α-induced chemotaxis in CCR1 transfectants and eotaxin-induced chemotaxis in CCR3 transfectants, with respective half-maximal inhibitory concentrations (IC50) of 9.57 nM and 93.8 nM [1] [2].</p>Fórmula:C30H37Cl2IN2O2Cor e Forma:SolidPeso molecular:655.44BMS-639623
CAS:<p>BMS-639623 is a CCR3 antagonist with a picomolar inhibitory effect on eosinophilic chemotaxis and can be used in the treatment of asthma.</p>Fórmula:C25H32FN7O2Cor e Forma:SolidPeso molecular:481.57LMD-009
CAS:<p>LMD-009 is a non-peptide, selective CCR8 agonist that mediates chemotaxis, inositol phosphate accumulation, and calcium release, with an EC50 of 11–87 nM.</p>Fórmula:C29H33N3O3Pureza:98%Cor e Forma:SolidPeso molecular:471.59K777
CAS:<p>K777: Oral cysteine protease inhibitor, CYP3A4 blocker (IC50=60 nM), CCR4 antagonist, anti-Trypanosoma cruzi, antiviral, halts EBOV/SARS-CoV entry (IC50<1 nM).</p>Fórmula:C32H38N4O4SPureza:98.43% - 99.14%Cor e Forma:SolidPeso molecular:574.73CCR3 antagonist 1
CAS:<p>CCR3 antagonist 1 is a potent CCR3 antagonist, used for the research of inflammatory and immunologic diseases.</p>Fórmula:C19H21Cl2N3O4S2Pureza:98.28%Cor e Forma:SolidPeso molecular:490.42INCB3344
CAS:<p>INCB3344 is an effective, specific and orally bioavailable CCR2 antagonist with IC50 values of 9.5 nM (mCCR2) and 5.1 nM (hCCR2) in binding antagonism and 7.8</p>Fórmula:C29H34F3N3O6Pureza:98% - 98.2%Cor e Forma:SolidPeso molecular:577.59CP-865569
CAS:<p>CP-865569 is a CCR1 antagonist useful in the research of inflammatory and autoimmune diseases, including conditions such as rheumatoid arthritis and multiple sclerosis.</p>Fórmula:C22H26ClFN2O5SCor e Forma:SolidPeso molecular:484.969Aplaviroc
CAS:<p>Aplaviroc (AK 602), a SDP derivative, is a CCR5 antagonist. With IC50s of 0.1-0.4 nM for HIV-1Ba-L, HIV-1JRFL and HIV-1MOKW.</p>Fórmula:C33H43N3O6Pureza:97.98% - 98.26%Cor e Forma:SolidPeso molecular:577.71CCR5 antagonist 1
CAS:<p>CCR5 antagonist 1 is a CCR5 antagonist extracted from WO 2004054974 A2. It can inhibit HIV replication.</p>Fórmula:C39H46ClF2N5O3SPureza:98%Cor e Forma:SolidPeso molecular:738.33CXCR2/CCR7 antagonist-1
CAS:<p>CXCR2/CCR7 antagonist-1 (compound 6) is a potent dual antagonist of CXCR2 and CCR7, with IC50 values of 0.0046 μM and 0.0014 μM, respectively. It is valuable for research in tumor metastasis and autoimmune diseases.</p>Fórmula:C23H27N3O5Cor e Forma:SolidPeso molecular:425.48CCR7 Ligand 1
CAS:<p>CCR7-Cmp2105 is a thiadiazole-dioxide allosteric antagonist for CCR7 with a Kd of 3 nM and IC50 of 7.3 μM against arrestin binding.</p>Fórmula:C22H29N5O5SCor e Forma:SolidPeso molecular:475.56PF-07054894
CAS:<p>PF-07054894: potent CCR6 antagonist, targets GPCR, for inflammatory bowel disease research.</p>Fórmula:C24H30N6O4Cor e Forma:SolidPeso molecular:466.53Aplaviroc hydrochloride
CAS:<p>Aplaviroc, a potent CCR5 inhibitor, binds selectively, blocking HIV entry and specific monoclonal antibody attachment in vitro.</p>Fórmula:C33H44ClN3O6Cor e Forma:SolidPeso molecular:614.17INCB-9471 dihydrochloride
CAS:<p>INCB-9471 HCl: a potent CCR5 antagonist, blocks monocyte migration & HIV-1.</p>Fórmula:C30H42Cl2F3N5O2Pureza:98%Cor e Forma:SolidPeso molecular:632.59CCR1 antagonist 11 hydrochloride
<p>Oral CCR1 antagonist A1B1 targets h/m/rCCR1 (IC50: 0.03/0.58/0.32 μM), potential for treating inflammatory diseases.</p>Cor e Forma:SolidTAK-661
CAS:<p>TAK-661 is an inhibitor of eosinophil chemotaxis (eosinophil chemotaxis) that significantly alleviates late-phase bronchoconstriction while inhibiting the proliferation of eosinophils in bronchoalveolar lavage (BAL) and their infiltration into the airway walls.</p>Fórmula:C13H21N5O3SCor e Forma:SolidPeso molecular:327.40CP-481715
CAS:<p>CP 481715 is an effective selective CCR1 antagonist with potential therapeutic significance for inflammatory diseases.</p>Fórmula:C26H31FN4O4Cor e Forma:SolidPeso molecular:482.55Ophiobolin C
CAS:<p>inhibitor of human CCR5 binding to HIV-1 gp120</p>Fórmula:C25H38O3Pureza:98%Cor e Forma:SolidPeso molecular:386.57BAY-3153
CAS:<p>BAY-3153 is a selective CCR1 ( C-C motif chemokine receptor 1 ) antagonist (human IC 50 =3 nM ; rat IC 50 =11 nM ; mice IC 50 =81 nM) .</p>Fórmula:C25H29Cl2N3O4Cor e Forma:SolidPeso molecular:506.42BI 639667
CAS:<p>BI 639667, an azaindazole-class compound, potently inhibits CCR1 (IC50=1.8 nM in calcium flux assays).</p>Fórmula:C22H18FN5O3SPureza:99.86%Cor e Forma:SolidPeso molecular:451.47CCR1 antagonist 13
CAS:<p>CCR1 antagonist13 is a selective small molecule antagonist of CCR1.</p>Fórmula:C25H27ClFN3O4Cor e Forma:SolidPeso molecular:487.95BMS-741672
CAS:<p>BMS-741672 is a potent, selective CCR2 antagonist for the treatment of neuropathic pain.</p>Fórmula:C25H33F3N6O2Cor e Forma:SolidPeso molecular:506.56Nifeviroc
CAS:<p>Nifeviroc (TD-0232) is an orally active CCR5 antagonist, useful in HIV-1 infection research.</p>Fórmula:C33H42N4O6Pureza:98.14%Cor e Forma:SolidPeso molecular:590.71MK-0812
CAS:<p>MK-0812 is a dual antagonist of the CCR2 and CCR5 receptors that can alleviate adipose inflammation in ob/ob mice.</p>Fórmula:C24H34F3N3O3Pureza:98%Cor e Forma:SolidPeso molecular:469.54AZD-5672
CAS:<p>AZD-5672 is an antagonist of CCR5 with an IC50 of 0.32 nM.</p>Fórmula:C32H38F2N2O5S2Pureza:98.1%Cor e Forma:SolidPeso molecular:632.78BX471 hydrochloride
CAS:<p>BX471 hydrochloride (ZK-811752 hydrochloride) is a potent, selective non-peptide CCR1 antagonist with a Ki of 1 nM for human CCR1, exhibiting 250-fold selectivity over CCR2, CCR5, and CXCR4.</p>Fórmula:C21H25Cl2FN4O3Pureza:98%Cor e Forma:SolidPeso molecular:471.35
![CCR2-RA-[R]](/_next/image/?url=https%3A%2Fstatic.cymitquimica.com%2Fproducts%2FTM%2Fthumb-webp%2FT14900.webp&w=3840&q=75)
